Intra-cellular Therapies Stock News

The company is floating at least $400 million worth of its common stock.

The company is floating at least $400 million worth of its common stock.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Liquidia Appoints Pharma Industry Veteran Roger Jeffs As CEO Liquidia Corporation (NASDAQ: LQDA) annou

Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones and S&P 500 closed at fresh highs on the first trading day of new year. Investors are awaiting earnings r

Some of the stocks that may grab investor focus today are: Wall Street expects SMART Global Holdings, Inc. (NASDAQ: SGH) to report quarterly earnings at $2.00 per share on revenue of $460.17 million

Intra-Cellular Therapies Inc (NASDAQ: ITCI) commenced an underwritten public offering of $400 million of shares. Underwriters have an option to purchase up to an additional 15% of the shares of comm

NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ne

Related Stocks: ITCI ,

Intra-Cellular Therapies (NASDAQ:ITCI) had its target price raised by Needham & Company LLC from $55.00 to $59.00 in a report released on Monday morning, Analyst Price Targets reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical companys stock. A number of other research firms have also weighed in on ITCI. Zacks [] The post Intra-Cellular Therapies (NASDAQ:ITCI) PT Raised to $59.00 at Needham & Company LLC appeared first on ETF Daily News .

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CFO Lawrence J. Hineline sold 175,000 shares of the companys stock in a transaction on Tuesday, December 21st. The shares were sold at an average price of $47.59, for a total value of $8,328,250.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible []

Intra-Cellular Therapies is rewarding shareholders while bringing stellar medicine to patients suffering from psychiatric conditions. As a differentiated neuroleptic, Caplyta demonstrated robust effic

Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) saw unusually-high trading volume on Tuesday after Royal Bank of Canada raised their price target on the stock from $50.00 to $55.00. Royal Bank of Canada currently has an outperform rating on the stock. Approximately 37,214 shares changed hands during mid-day trading, a decline of 93% from the previous []

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)s share price shot up 5.6% during trading on Wednesday after Royal Bank of Canada raised their price target on the stock from $50.00 to $55.00. Royal Bank of Canada currently has an outperform rating on the stock. Intra-Cellular Therapies traded as high as $50.98 and last traded at $50.90. 31,486 shares []